Enrolling
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
J1I-MC-GZQA - ClinicalTrials.gov - NCT06297603
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor.
Enter your city or zip code to find the nearest site
Trial Summary
Age Range
≥18 yearsConditions the trial is for
Type 2 diabetesWhat the trial is testing?
retatrutideCould I receive a Placebo?
YesEnrollment Goal
320Trial Dates
Mar 15, 2024 - Oct 2026How long will I be in the trial?
The study will last about 14 months and may include up to 22 visits.Trial Phase
IIIKey Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Be 18 years or older
Have a BMI of ≥ 23.0 kg/m^2
Have Type 2 Diabetes
Have high blood sugar as measured by hemoglobin A1C (HbA1c at least 7%)
Have impaired kidney function, an eGFR 15 to <60 mL/min/1.73 m2
Be taking basal Insulin
Participants Must Not:
Have Type 1 Diabetes
Have had or plan to have a surgical treatment for obesity
Have history of an inflamed pancreas (pancreatitis)
Have used any weight loss drugs within the last 3 months
Lilly Trial Alerts
Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo